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Accepted 22 March 2016; Published online 29 March 2016AbstractObjectives: The inclusion of musculoskeletal conditions within multimorbidity research is inconsistent, and working-age populations
are largely ignored. We aimed to: (1) estimate multimorbidity prevalence among working-age individuals with a range of musculoskeletal
conditions; and (2) better understand the implications of decisions about the number and range of conditions constituting multimorbidity on
the strength of associations between multimorbidity and burden (e.g., health status and health care utilization).
Study Design and Setting: Using data from the Australian National Health Survey 2007e08, the associations between burden
measures and three ways of operationalizing multimorbidity (survey, policy, and research based) within the working-age (18e64 years)
musculoskeletal population were estimated using multiple logistic regression (age and gender adjusted).
Results: Depending on definition, from 20.2% to 75.4% of working-age individuals with musculoskeletal conditions have multimor-
bidity. Irrespective of definition, multimorbidity was associated with increased likelihood of subjective health burden, pain or musculoskel-
etal medicines use, nonmusculoskeletal specialist and pharmacist (advice only) consultations, and reduced likelihood of not consulting
health professionals. A group with intermediate health outcomes was considered multimorbid by some, but not all definitions. With the
restrictive policy and research multimorbidity definitions, this intermediate group is included within the reference population (i.e., are
considered nonmultimorbid). This worsens the reference group’s apparent health status thereby leveling the comparative burden between
those with and without multimorbidity. Consequently, dichotomous cut points lead to similar associations with burden measures despite the
increasingly restrictive multimorbidity definitions used.
Conclusions: All multimorbidity definitions were associated with burden among the working-age musculoskeletal population. Howev-
er, dichotomous cut points obscure the gradient of increased burden associated with restrictive definitions.  2016 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The importance of coexisting chronic conditions (termed
multimorbidity [1], or in the context of an index condition,
comorbidity [2]) is increasingly recognized becauseFunding: This work was supported by an Alice O’Brien, Arthritis and
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licenses/by-nc-nd/4.0/).multimorbidity magnifies health care expenditure [3],
health care service usage [4,5], polypharmacy, and mortal-
ity rates [6]; reduces functional status and quality of life
[7e12]; and contributes to adverse events [12]. Multimor-
bidity prevalence varies substantially across studies,
ranging from 12% to 95% [3,7,13e22]. Factors contrib-
uting to this variation include differences in geographical
settings, populations sampled, and data collection methods
[17,23].
There is currently no ‘‘gold standard’’ definition for
multimorbidity (or comorbidity). The definition selected
depends on its suitability for the sample population,
outcome of interest, or the data available [7,11,22,24].
Complex scaleebased measures of coexistent conditions
that include weightings of severity [25e28] or physicaless article under the CC BY-NC-ND license (http://creativecommons.org/
117cal Epidemiology 78 (2016) 116e126What is new?
Key findings
 The estimate of prevalence of multimorbidity in
the working-age Australian population with
musculoskeletal conditions varies greatly with
how multimorbidity is defined (i.e., with the sur-
vey, policy, and research definitions).
 Irrespective of definition, multimorbidity adds to
subjective health burden and health care
utilization.
What this adds to what was known?
 The strength of associations between multimorbid-
ity and burden is relatively consistent with these
different multimorbidity operational definitions
(establishing convergent validity).
 However, an inherent limitation of dichotomous
cut points is that they ‘‘level associations’’ and
obscure the gradient of increased burden associated
with the more restrictive definitions.
 The degree of burden added by multimorbidity es-
calates with each increasingly restrictive opera-
tional definition; however, this is illustrated only
when the reference group is fixed to those consid-
ered not multimorbid by any definition (examined
here).
What is the implication and what should change
now?
 It is important to be aware of this ‘‘leveling of as-
sociation’’ with burden measures when comparing
different definitions of multimorbidity based on
simple counts.
D. Lowe et al. / Journal of Clinifunctioning [29,30] potentially require intensive training
time or labor to implement, access to clinical notes [24],
and researcher decisions about presence of conditions are
still partly subjective [7]. Data on duration, time-course,
or severity of disease are often limited, which precludes
weighting on these factors [23]. Therefore, multimorbidity
is often pragmatically operationalized by simply summing
the number of coexisting chronic diseases [11,31,32]. In
addition, the minimum number (nominal threshold) and
range (operational definition) of conditions that constitute
multimorbidity contribute to the heterogeneity in preva-
lence observed across study populations [11,18,23,33e35].
Multimorbidity operationalized by condition count can
include all conditions reported individually [11,36] or cate-
gorized by affected organs or systems [17,23]; the range of
chronic conditions reported may be unlimited, or limited toa prespecified list of conditions. Even within a single data
set, the definition used (‘‘survey’’ [37], ‘‘policy’’ [38],
and ‘‘research based’’ [35]) to operationalize multimorbid-
ity greatly influences prevalence estimates (Lowe et al. sub-
mitted and [34]). However, it is unclear whether the
strength of associations between these multimorbidity oper-
ational definitions and burden (e.g., health status and health
care utilization) similarly varies. Examination of how well
multimorbidity based on simple counts encapsulate
associated health burden is needed to establish convergent
validity of these multimorbidity definitions and to better
understand the implications of decisions about the range
of conditions included.
Working-age people with musculoskeletal (MSK) condi-
tions are an appropriate policy-relevant and clinically impor-
tant population to determine the additional subjective health
and health care utilization burden that can be attributed to the
presence of multimorbidity. MSK are highly prevalent and
therefore a likely component of multimorbidity [7,21,39].
MSK are demonstrably burdensome; they impact on quality
of life [40], complexity of medication regimens [41], and
ability to continue paid employment [16,42]. Problemati-
cally, multimorbidity research tends to include MSK in an
inconsistent and selective manner (e.g., restricted to osteoar-
thritis [43]; fibromyalgia and rheumatic conditions [21,44])
or within vaguely described or broadly encapsulating
categories (e.g., inclusive of arthritis, joint disorders, or
painful conditions not otherwise described [7,12]). Further-
more, multimorbidity research typically focuses on older
people; however, similar to MSK, multimorbidity is not
simply a process of aging [7,19,22]. Consequently, little is
known about the additional subjective burden of multimor-
bidity among working-age people with MSK [10].
To address this, we used data from the Australian Na-
tional Health Survey, to answer the following questions.
Among working-age (18e64 years) people with any MSK:
1. Is each multimorbidity definition associated with
additional burden across a range of subjective health
and health care utilization measures? (i.e., establish
convergent validity)
2. Do these observed associations vary according to the
multimorbidity definition used?2. Materials and methods
Data were sourced from the Australian Bureau of Statis-
tics (ABS) National Health Survey 2007-08 [National
Health Survey (NHS) 07-08] [37]. The ABS conducts
NHS on a regular, approximately triennial basis. This sec-
ondary analysis uses data from a survey that took place dur-
ing the period of August 2007 to June 2008. Previous
surveys were conducted in 1977e78, 1983, 1989e90,
1995, 2001 and 2004e05. Confidentialized unit record
files, released by the ABS since 2001, enable researchers
to conduct detailed analysis of the survey data. For this
118 D. Lowe et al. / Journal of Clinical Epidemiology 78 (2016) 116e126nationally representative survey, the ABS sampled people
from all Australian states and territories and across all
age groups. The overall response rate for the NHS 07-08
was 91%. In total, 20,788 persons from 15,792 households
provided completed questionnaires. The NHS 07-08 ques-
tionnaire sought data on a broad range of health factors
including self-reports of conditions diagnosed, health sta-
tus, use of health services, health-related lifestyle risk fac-
tors, and sociodemographic characteristics. Information
was collected through trained interviewers using prompt
cards and where possible, with validated measures. Further
details on survey design, sampling strategy, questionnaire,
and response rate are available elsewhere [37].
For the present study, the sample population was drawn
from working-age (18e64 years) NHS 07-08 respondents
(n 5 12,604) who self-reported the presence of any chronic
(i.e., current and present for 6 months or more) MSK con-
dition(s) (n 5 4,555; 36.1% of working-age sample). MSK
comprised any of: osteoarthritis (n 5 933; 7.9%), inflam-
matory arthritis (n 5 317; 2.5%), other arthritis or arthrop-
athies (n 5 1,022; 8.1%), soft-tissue disorders (n 5 404;
3.2%), gout (n 5 589; 4.7%), back pain (n 5 2,493;
19.8%), osteoporosis (n 5 292; 2.3%), or other MSK
(n 5 117; 0.9%).
The multimorbidity operational definitions compared
were drawn from ‘‘survey-’’ [37], ‘‘policy-’’ [38] and
‘‘research-based’’ [35] contexts. The survey definition
included all chronic conditions reported within the NHS
07-08. The policy definition included Australian National
Health Priority Area chronic condition categories: MSK,
diabetes, cancer, cardiovascular disease, asthma, chronic
obstructive pulmonary disease, and mental health disorders
[38]. By collating conditions into categories, the definition
counts two or more conditions (e.g., osteoporosis and rheu-
matoid arthritis) affecting a single body system only once
(e.g., MSK). The research definition included: cancer, dia-
betes mellitus, depression, hypertension, myocardial infarc-
tion, chronic ischemic heart disease, heart arrhythmias,
heart insufficiency, stroke, chronic obstructive pulmonary
disease, and arthritis [35]. Details on specific diagnoses
included in each condition category are described in more
detail elsewhere ([35,37,38] and Lowe et al. submitted).
The nominal threshold (minimum number of conditions
constituting multimorbidity) varied between definitions.
For the policy and research definitions of multimorbidity,
it was two or more (2þ) chronic condition categories. For
the survey definition, with the 2þ threshold, multimorbidity
prevalence within the working-age MSK population was
very high, resulting in small cell counts in many instances
and therefore associations could not be estimated. There-
fore, the multimorbidity threshold for the survey definition
was set at 3þ conditions (as recommended in Lowe et al.
submitted). This higher threshold was required as the
survey definition includes all reported chronic conditions,
some with potentially insubstantial burden (e.g., myopia).Subjective health burden (during 4 weeks before
interview) included NHS 07-08 measures of: fair to poor
self-rated health status [45], high psychological distress
[46], moderate to severe pain rating, and pain interfering
with work (see Table 1).
MSK-related medicines use and health care utilization
data were collected only for respondents with current
long-term osteoporosis, osteopenia, arthritis [gout, rheuma-
tism or arthritis - osteoarthritis, rheumatoid arthritis, and/or
other type (specified)]. General health care utilization data
were collected from all respondents. Health utilization
measures were based on the following NHS 07-08 data:
 Pain and MSK-related medicines use in the previous
2 weeks. MSK-related medicines use included self-
reports of up to three arthritis-related, self-reported main
pharmaceuticals used. This included vitamins and min-
eral supplements such as vitamin D, calcium, glucos-
amine, and various marine-based products, natural, or
herbal treatments;
 MSK-related general practitioner (GP) and specialist
consultations during the previous 2 weeks (e.g., for
arthritis or osteoporosis);
 General health care utilization during the previous
12 months including consulting a specialist, physio-
therapist(s), chiropractor(s), or pharmacist(s) for
advice, as well as, not consulting a health professional.
All statistical analyses were performed using Stata
(release 10.1, College Station, TX, USA). The associations
between multimorbidity and the various outcomes among
the MSK population were estimated using multiple logistic
regression models. Analyses were adjusted for age and
gender as potential confounders. To account for the survey
design, the ABS generated replicant weights were applied.
Based on weights provided in the confidentialized unit re-
cord file, population prevalence estimates of multimorbid-
ity for each of the operational multimorbidity definitions
were derived for the total working-age MSK population,
as well as age- and gender-specific subgroups.
Previously (Lowe et al. submitted), we demonstrated the
survey definition is the most inclusive and the research defi-
nition, by including only conditions purported to be severely
problematic to health, the most restrictive. With dichoto-
mous multimorbidity measures, the more restrictive the defi-
nition is, the more peopledincluding individuals with
potentially burdensome health (see intermediate group in
Fig. 1)dare placed into the nonmultimorbid reference
group. We explored the effects of these dichotomous cut
points further by identifying the group considered univer-
sally by the three definitions as ‘‘nonmultimorbid,’’ as a sta-
ble reference group. To achieve this, we created four
mutually exclusive groups: (1) ‘‘nonmultimorbid’’ according
to any definition, (2) ‘‘multimorbid with the survey definition
only,’’ (3) ‘‘multimorbidwith both the policy and survey defi-
nition,’’ and (4) ‘‘multimorbid with all three definitions.’’
Table 1. Description of self-reported health measures
Health measure Description Timeframe
Fair to poor self-rated health status A response of either ‘‘fair’’ or ‘‘poor’’ to the question ‘‘In general
would you say that [your/(proxy name)] health is excellent, very
good, good, fair, or poor’’
During 4 weeks before interview
High psychological distress A Kessler Psychological Distress Scale-10 (K10) grouped score
indicating high (O22 points) or very high severity of distress
(30e50 points)
During 4 weeks before interview
Moderate to severe pain A rating of ‘‘moderate,’’ ‘‘severe,’’ or ‘‘very severe’’ to the extent of
bodily pain felt
During 4 weeks before interview
Pain interfering with work A response of ‘‘moderately’’ or ‘‘extremely’’ to the extent of bodily
pain interfering on normal work activities
During 4 weeks before interview
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3.1. Characteristics of MSK population and prevalence
of multimorbidity
Prevalence of most demographic characteristics, multi-
morbidity, subjective health, and health care utilization
measures varied between working-age respondents with
or without MSK (Table 2). Among the working-age popu-
lation, people with MSK were older and had lower house-
hold income than those without MSK: the prevalence of
multimorbidity was as low as 20.2% with the research defi-
nition, 38.3% with the policy definition, and as high as
75.4% with the survey definition. Ratings of all subjective
health and health utilization measures were higher for those
with MSK than the working-age population without (see
Table 2).
For each multimorbidity definition, the proportion of the
MSK population considered multimorbid increases with
age and differs slightly by gender (see Fig. 2). To determine
if reporting strata-specific estimates were warranted, weFig. 1. Illustration of dichotomous population cut points for those considered
on health along a continuum. MSK, musculoskeletal.formally tested whether either gender or age modified the
associations between multimorbidity and self-reported
health outcomes, using interaction analyses. These analyses
revealed no clinically important effect modification by
either gender or age. For example, while women are more
likely to report psychological distress than males, the asso-
ciation between multimorbidity and psychological distress
is nonetheless similar for both males and females. Where
effect modification was observed, associations were stron-
ger in some subgroups, but the direction of effects was
the same (results available on request).3.2. Associations between multimorbidity and
subjective health measures
In the working-age population with any MSK condition
(here onward termed the MSK population), the presence of
multimorbidity with each definition was associated with
increased likelihood of poorer ratings for all subjective
health measures, compared to the MSK population withoutto have multimorbidity with each definition and hypothesized burden
Table 2. Prevalence of demographic characteristics, multimorbidity, subjective health, and health care utilization measures within the working-age
(18 to 64 years) respondents with or without MSK (adjusted for survey design)
Characteristic
Working-age population with MSK
(n [ 4,555); prevalence % (95% CI)
Working-age population without MSK
(n [ 8,049); prevalence % (95% CI)
Gender
Female 50.3 (48.6, 52.1) 50.0 (49.0, 51.0)
Male 49.7 (47.9, 51.4) 50.0 (49.0, 51.0)
Age group
18e34 21.5 (20.0, 23.1) 45.0 (44.1, 45.9)
35e49 34.8 (33.5, 36.2) 34.5 (33.7, 35.2)
50e64 43.7 (42.1, 45.2) 20.5 (19.7, 21.3)
Income group
First quintile 13.6 (12.2, 15.1) 7.5 (6.9, 8.1)
Second quintile 14.9 (13.5, 16.5) 14.1 (13.0, 15.4)
Third quintile 19.6 (18.2, 21.1) 19.2 (18.0, 20.4)
Fourth quintile 19.1 (17.2, 21.1) 21.6 (20.4, 22.9)
Fifth quintile 17.9 (16.5, 19.5) 22.0 (20.6, 23.5)
Not stated 14.8 (13.5, 16.4) 15.6 (14.3, 16.9)
Multimorbidity
Survey definitiona 75.4 (73.6, 77.0) 24.8 (23.5, 26.2)
Policy definitionb 38.3 (36.5, 40.1) 3.5 (3.0, 4.1)
Research definitionc 20.2 (18.9, 21.6) 1.7 (1.4, 2.0)
Subjective health measures during previous month
Fair to poor health status 22.2 (20.6, 23.8) 7.5 (6.8, 8.2)
High psychological distress 19.0 (17.5, 20.7) 9.1 (8.2, 10.1)
Moderate to severe pain rating 46.1 (44.5, 47.8) 16.7 (15.6, 17.9)
Pain interfering with work 36.0 (34.0, 37.9) 12.6 (11.7, 13.7)
Health care utilization measures (MSK related) within last 2 weeks
Consulting an MSK specialist 2.2 (1.7, 2.8) Not applicable
Consulting GP for MSK condition 4.4 (3.7, 5.3) Not applicable
Pain medication use 4.9 (4.0, 5.8) 0.7 (0.5, 1.0)
MSK medication use 24.4 (22.7, 26.2) 0.7 (0.5, 0.9)
Health care utilization measures during previous 12 months (general)
Consulting a specialist 32.6 (30.9, 34.4) 18.9 (17.9, 20.90)
Consulting a physiotherapist 14.0 (12.7, 15.4) 7.5 (6.7, 8.4)
Did not consult health professional 31.8 (30.0, 33.6) 50.8 (49.2, 52.5)
Consulting a pharmacist (advice only) 16.6 (15.4, 17.9) 12.4 (11.3, 13.6)
Consulting a chiropractor 15.2 (13.7, 16.8) 7.5 (6.8, 8.2)
Abbreviations: MSK, musculoskeletal; CI, confidence interval; GP, general practitioner.
a The survey definition includes the presence of three or more conditions reported within the NHS 07-08.
b The policy definition includes the presence of two or more Australian National Health Priority Area conditions: MSK, diabetes, cancer, car-
diovascular disease, asthma, chronic obstructive pulmonary disease, and mental health disorder.
c The research definition suggested by Diederichs et al. includes two or more of the following conditions: cancer, diabetes mellitus, depression,
hypertension, myocardial infarction, chronic ischemic heart disease, heart arrhythmias, heart insufficiency, stroke, chronic obstructive pulmonary
disease, and arthritis.
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with multimorbidity were 2.8-fold to 3.9-fold more likely
to report fair to poor health status, and twice as likely to
report higher ratings of pain, or pain interfering with work,
than the MSK population without multimorbidity. The
strongest association was observed for psychological
distress: the MSK population with multimorbidity was
3.0-fold to 6.6-fold more likely to report high psychological
distress than those without multimorbidity (see Table 3).
Associations between multimorbidity and subjective
health measures were similar, regardless of the definition
used (Table 3), with most confidence intervals (CIs) over-
lapping. Two possible exceptions to this were: (1) the likeli-
hood of high psychological distress was greater with the
policy definition; and (2) the association with poor to fairhealth status was slightly weaker with the survey definition
(see Table 3).
As it is questionable if nonlower back pain is truly an
MSK [47], we conducted analyses excluding those partici-
pants with only back pain and no other form of MSK. The
results were substantively similar, with the exception that
the associations with psychological distress were margin-
ally weaker (analyses available on request).3.3. Associations between multimorbidity and self-
reported MSK-related health care utilization
Among the MSK population, the presence of multimor-
bidity was associated with increased likelihood of using
pain or MSK medications, compared to the MSK
a The survey definiƟon includes all condiƟons reported within the NHS 07-08. 
b The policy definiƟon includes Australian NaƟonal Health Priority Area condiƟons: MSK, diabetes, cancer, 
cardiovascular disease, asthma, chronic obstrucƟve pulmonary disease, and mental health disorder. 
c The research definiƟon suggested by Diederichs et al. includes:  cancer, diabetes mellitus, depression, 
hypertension, myocardial infarcƟon, chronic ischemic heart disease, heart arrhythmias, heart insuﬃciency, 
stroke, chronic obstrucƟve pulmonary disease, and arthriƟs.
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Fig. 2. Age- and gender-specific prevalence rates of multimorbidity
among the working-age MSK population obtained with the surveya,
policyb, and researchc multimorbidity definitions, respectively. aThe
survey definition includes all conditions reported within the NHS
07-08. bThe policy definition includes Australian National Health Pri-
ority Area conditions: MSK, diabetes, cancer, cardiovascular disease,
asthma, chronic obstructive pulmonary disease, and mental health
disorder. cThe research definition suggested by Diederichs et al. in-
cludes: cancer, diabetes mellitus, depression, hypertension, myocar-
dial infarction, chronic ischemic heart disease, heart arrhythmias,
heart insufficiency, stroke, chronic obstructive pulmonary disease,
and arthritis. MSK, musculoskeletal.
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associated with increases in associations with MSK-related
GP or MSK specialist consultations in the previous 2 weeks
among the MSK population (see Table 4).
The point estimates for associations between multimor-
bidity and MSK-related health care utilization were fairly
similar (and CIs overlap) regardless of definition used.
Within the MSK population, the association with pain
medication use was strongest with multimorbidity using
the policy definition, whereas association with MSK
medication use was strongest with multimorbidity using
the survey definition (see Table 4).
3.4. Associations between multimorbidity and
self-reported general health care utilization
Within the MSK population, the presence of multimor-
bidity was associated with a twofold increase in consulting‘‘other’’ specialists (i.e., non-MSK related), pharmacists for
advice only (i.e., not for prescription refill), and a reduced
likelihood of not consulting a health professional during the
last 12 months. Presence of multimorbidity was not consis-
tently associated with consulting either a chiropractor or
physiotherapist among the MSK population (Table 5).
The associations with general health care utilization did
not vary substantiallywith themultimorbidity definition used
(see Table 5). One exception was consulting with a chiro-
practor. This was associated with a slightly increased likeli-
hood with the survey definition, whereas for the research
definition, the associations were reduced and the policy defi-
nition was not associated with consulting a chiropractor.3.5. The effect of shifting ‘‘nonmultimorbid’’ reference
groups on associations with burden measures
There was a clear gradient of increasing burden associ-
ated with the restrictiveness (i.e., decreased prevalence)
of the multimorbidity definition when compared to those
who were ‘‘nonmultimorbid’’ according to all three defini-
tions (Table 6). Within Tables 3e5, as the multimorbidity
definition becomes more restricted, more people, including
individuals with progressively poorer health status (as illus-
trated by the shaded cells in Table 6), were placed into the
reference (‘‘nonmultimorbid’’) group. This shifting inter-
mediate group (Fig. 1) has the effect of worsening the refer-
ence group’s apparent health status, leveling the
associations between multimorbidity and burden measures,
consequently resulting in estimates that appear mostly uni-
form across definitions. However, when the reference group
is fixed to those considered ‘‘nonmultimorbid’’ by all three
definitions, the gradient in burden associated with each
mutually exclusive multimorbidity group is clear, as indi-
cated by the point estimates and CIs no longer overlapping
(Table 6). Compared with those considered ‘‘nonmultimor-
bid’’ with any definition, those who were considered multi-
morbid by all three definitions had an 8.5-fold higher odds
of reporting fair to poor health, 8.9-fold increased odds of
high psychological distress, 3.4-fold increased odds of pain
interfering with work, and 4.0-fold increased odds of re-
porting a moderate to severe pain rating.4. Discussion
For the sample population of working-age Australians
with any MSK, multimorbidity (however defined) was
associated with higher subjective health burden (fair to poor
health status, high psychological distress, moderate to se-
vere pain ratings, and pain interfering with work) when
compared to people with MSK but without multimorbidity.
Similarly, irrespective of definition used, multimorbidity
was associated with health care utilization measures
including increased likelihood of consulting ‘‘other’’ spe-
cialists and pharmacist for advice only and pain or MSK
Table 3. Associations between multimorbidity and subjective health burden measures among the working-age musculoskeletal population
Multimorbidity definition
(condition threshold)
Fair to poor health
status; OR (95% CI)
High psychological
distress; OR (95% CI)
Pain interfering with
work; OR (95% CI)
Moderate to severe pain
rating; OR (95% CI)
Surveya (3þ) 2.8 (2.1, 3.7) 3.3 (2.4, 4.5) 2.1 (1.6, 2.6) 2.4 (1.9, 2.9)
Policyb (2þ) 3.9 (3.1, 4.8) 6.6 (5.4, 8.1) 2.2 (1.8, 2.7) 2.1 (1.7, 2.5)
Researchc (2þ) 3.9 (3.0, 4.9) 3.0 (2.3, 3.9) 1.8 (1.4, 2.3) 2.1 (1.7, 2.6)
Abbreviations: OR, odds ratio; CI, confidence interval; MSK, musculoskeletal.
The reference group is the MSK working-age population without multimorbidity (as classified per the definition in the row). Associations are
adjusted for age and gender.
a The survey definition includes all conditions reported within the NHS 07-08.
b The policy definition includes Australian National Health Priority Area conditions: MSK, diabetes, cancer, cardiovascular disease, asthma,
chronic obstructive pulmonary disease, and mental health disorder.
c The research definition suggested by Diederichs et al. includes: cancer, diabetes mellitus, depression, hypertension, myocardial infarction,
chronic ischemic heart disease, heart arrhythmias, heart insufficiency, stroke, chronic obstructive pulmonary disease, and arthritis.
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of multimorbidity did not generally alter likelihood of
consulting a specialist or GP for MSK-related issues, or
consulting physiotherapist or chiropractor. This is an ex-
pected finding because multimorbities are not usually
treated by those professionals, but by ‘‘other specialists.’’
Each definition used here ‘‘counts’’ conditions differ-
ently, and this has important implications. For the policy
definition, the ‘‘nonmultimorbid’’ reference population
potentially includes people with more than one condition
because this definition groups some individual conditions
into affected organ categories. This is done because the
number of body systems affected may be a better indica-
tor of severity of burden related to multimorbidity than
summing individual conditions [17]. For the survey defi-
nition, although all individual conditions reported were
summed, the three-condition threshold was used, so the
‘‘nonmultimorbid’’ reference population again potentially
includes people with two conditions. Yet, all three multi-
morbidity definitions compared here predicted almost
equivalently increased likelihood of subjective health
burden and health care utilization, even with organ
domainebased classification of conditions or when re-
stricting to conditions with a known burden, as with
the policy and research definitions. Our hypothesis was
that as populations classified with multimorbidity becomeTable 4. The association between the presence of multimorbidity and muscu
the previous 2 weeks, among the working-age MSK population
Multimorbidity definition
(condition threshold)
MSK-related specialist consultations;
OR (95% CI)
MSK-rela
Surveya (3þ) 3.4 (0.7, 17.8) 2
Policyb (2þ) 1.5 (0.8, 3.0) 1
Researchc (2þ) 1.7 (0.9, 3.6) 0
Abbreviations: OR, odds ratio; CI, confidence interval; GP, general prac
The reference group is the MSK working-age population without multim
adjusted for age and gender.
a The survey definition includes all conditions reported within the NHS
b The policy definition includes Australian National Health Priority Area
chronic obstructive pulmonary disease, and mental health disorder.
c The research definition suggested by Diederichs et al. includes: cance
chronic ischemic heart disease, heart arrhythmias, heart insufficiency, stromore restricted with each definition, the impact of multi-
morbidity would become more burdensome (see Fig. 1).
Therefore, this finding was unexpected, especially given
the very different estimates of multimorbidity prevalence
generated by these same definitions (range: 20.2% to
75.4%).
However, further analyses revealed that although all
three definitions predict similar additional health burden
associated with multimorbidity within the MSK population,
this is only the case when compared with those considered
‘‘nonmultimorbid’’ by the particular definition forming the
analysis. It is therefore misleading to conclude that the
burden associated with multimorbidity is uniform irrespec-
tive of conditions included, as there is a gradient of
increased burden with the increasingly restrictive nature
of these definitions. However, this gradient in severity is
identified only when the reference population is fixed to
those uniformly classed as ‘‘nonmultimorbid’’ by all three
definitions. This is an inherent limitation of dichotomous
cut points used when operationalizing multimorbidity with
counts of conditions. The inclusion of the intermediate
group (i.e., the shifting group who are considered to be
multimorbid by some definitions but not by others) in the
reference population worsens the reference group’s
apparent health status thereby leveling the comparative
burden between those with and without multimorbidity.loskeletal (MSK)erelated health care utilization and medicines use in
ted GP consultations;
OR (95% CI)
Pain medication use;
OR (95% CI)
MSKa medication use;
OR (95% CI)
.1 (0.7, 6.0) 2.9 (1.5, 5.6) 2.1 (1.5, 2.9)
.5 (1.0, 2.2) 3.3 (2.2, 5.0) 1.4 (1.1, 1.7)
.9 (0.6, 1.5) 2.5 (1.6, 3.9) 1.8 (1.5, 2.3)
titioner.
orbidity (as classified per the definition in the row). Associations are
07-08.
conditions: MSK, diabetes, cancer, cardiovascular disease, asthma,
r, diabetes mellitus, depression, hypertension, myocardial infarction,
ke, chronic obstructive pulmonary disease, and arthritis.
Table 5. The association between the presence of multimorbidity and general health care utilization during the previous 12 months, among the
working-age musculoskeletal population
Multimorbidity definition
(condition threshold)
Consulting
a specialist;
OR (95% CI)
Consulting a
physiotherapist;
OR (95% CI)
Did not consult health
professional;
OR (95% CI)
Consulting a pharmacist
(advice only); OR (95% CI)
Consulting a chiropractor;
OR (95% CI)
Surveya (3þ) 2.1 (1.6, 2.7) 1.3 (0.9, 1.9) 0.5 (0.4, 0.6) 2.3 (1.6, 3.2) 1.2 (1.0, 1.6)
Policyb (2þ) 2.3 (1.9, 2.7) 1.0 (0.8, 1.4) 0.4 (0.4, 0.5) 2.0 (1.7, 2.5) 0.9 (0.7, 1.1)
Researchc (2þ) 2.0 (1.6, 2.6) 1.0 (0.7, 1.5) 0.5 (0.4, 0.7) 2.1 (1.6, 2.7) 0.6 (0.4, 0.9)
Abbreviations: OR, odds ratio; CI, confidence interval; MSK, musculoskeletal.
The reference group is the MSK working-age population without multimorbidity (as classified per the definition in the row). Associations are
adjusted for age and gender.
a The survey definition includes all conditions reported within the NHS 07-08.
b The policy definition includes Australian National Health Priority Area conditions: MSK, diabetes, cancer, cardiovascular disease, asthma,
chronic obstructive pulmonary disease, and mental health disorder.
c The research definition suggested by Diederichs et al. includes: cancer, diabetes mellitus, depression, hypertension, myocardial infarction,
chronic ischemic heart disease, heart arrhythmias, heart insufficiency, stroke, chronic obstructive pulmonary disease, and arthritis.
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burden that are relatively similar despite the greater severity
of conditions included in the more restrictive research defi-
nition compared to the policy definition and in both these
definitions compared to the survey definition. As such,
although the convergent validity of each operationalTable 6. Among the working-age population with MSK, the proportions w
multimorbidity is classed in distinct groups
Health measureb
Multimorbidity classed in
Nonmultimorbid
by all three
definitions (24.7%)
Multimor
survey de
only (36
Fair to poor health status 9.5% 13.9%
OR (95% CI) 1c 1.4 (1.0
OR for survey definition 1
OR for policy definition 1
OR for research definition 1
High psychological distress 8.5% 8.5%
OR (95% CI) 1 1.1 (0.7
OR for survey definition 1
OR for policy definition 1
OR for research definition 1
Mod-severe pain ratings 30.1% 42.9%
OR (95% CI) 1 1.7 (1.4
OR for survey definition 1
OR for policy definition 1
OR for research definition 1
Pain interfering with work 23.9% 31.9%
OR (95% CI) 1 1.5 (1.1
OR for survey definition 1
OR for policy definition 1
OR for research definition 1
a The groups are: ‘‘non-multimorbid’’ with all three definitions (fixed ref
only; classed as multimorbid with both the policy and survey definition; and
initions). Participants were excluded if they (1) met the policy definition but
not the survey definition (n 5 8), or (3) met the policy definition but not the
gender.
b The data from Table 2 are reanalysed here to highlight how the shifting
initions in contrast with the estimates produced by each definition when th
different to Table 2, due to the exclusion of participants outlined above.
c Shaded cells indicate nonmultimorbid reference group used in analysdefinition is relatively similar, it is important to be aware
of this ‘‘leveling of association’’ with burden measures
when using different definitions of multimorbidity.
The present study demonstrates that there are possibly
some specific instances where it does matter how multimor-
bidity is defined. With the policy definition multimorbidityith, and associations for, subjective health burden measures when
distinct groups (% of MSK working-age sample population)a
bid by
finition
.1%)
Multimorbid by
policy and survey
definitions (22.1%)
Multimorbid by research,
policy and survey
definitions (17.0%)
27.7% 50.6%
, 2.0) 3.5 (2.5, 5.0) 8.5 (5.9, 12.1)
2.9 (2.1, 4.0)
4.2 (3.4, 5.1)
4.7 (3.7, 6.1)
36.1% 37.7%
. 1.7) 6.4 (4.5, 9.3) 8.9 (5.9, 13.0)
3.6 (2.5, 5.0)
6.8 (5.6, 8.1)
4.0 (3.1, 5.2)
55.0% 63.3%
, 2.1) 2.7 (2.1, 3.5) 4.0 (3.0, 5.3)
2.3 (1.8, 2.8)
2.3 (1.8, 2.8)
2.3 (1.8, 2.9)
45.0% 51.5%
, 1.9) 2.6 (1.9, 3.4) 3.4 (2.4, 5.0)
2.1 (1.6, 2.7)
2.2 (1.8, 2.7)
2.1 (1.6, 2.8)
erence population); classed as multimorbid with the survey definition
classed as multimorbid with all three (survey, policy and research def-
not the survey definition (n 5 48), (2) met the research definition, but
research definition (n 5 178). Associations are adjusted for age and
reference group impacts the estimates of burden for each of the def-
e reference group is stable (fixed). The actual effect sizes are slightly
is for each row.
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pain medication, whereas the survey definition was more
strongly related to MSK medicine use, seeking advice only
from pharmacist (i.e., not to fill scripts) and visits to chiro-
practor. MSK-related GP consults also varied according
with multimorbidity definitions. Furthermore, the policy
definition was a better predictor of distress than the survey
and research definitions. This association does not appear to
be an artifact due to mental health being part of the multi-
morbidity definition because all three definitions included
chronic depression. Specifically, the survey and policy
definitions include all chronic mental health conditions re-
ported by respondents, whereas the research definition in-
cludes depression only.
The strength of this study was the use of a large nation-
ally representative data set, with a comprehensive range of
data on subjective health burden, health care and medicines
use, and chronic conditions available. By directly
comparing different operationalizations of multimorbidity
within a single sample population, we have shown that
the choice of definition directly affects burden estimates,
eliminating other explanatory factors including geograph-
ical setting, recruitment, and data collection methods.
Limitations of the data include that it is self-reported,
which may be subject to recall bias, and cross-sectional,
which does not allow for examination of temporality of as-
sociations between variables. In addition, given the
inability to rate clinical severity, we measured multimorbid-
ity by conditions counts.
The focus on the working-age, community dwelling
population extends multimorbidity research to illustrate
that multimorbidity is associated with additional impact
within this largely overlooked population [15,33]. Further-
more, by applying the definitions of multimorbidity with a
population with existing disease (people with any MSK),
we determined the additional burden associated with three
definitions of multimorbidity. The general consensus is
that when an index condition is applied, the term is co-
morbidity [1,2]; however, here, we use the term multimor-
bidity although we are also considering MSK. This is
because although the sample population is people with
any MSK, the exposure is the presence of multimorbidity;
thus, here, MSK is not an index condition. Instead, those
with MSK are the population within which the subjective
burden of multimorbid is compared to the subjective
burden of those considered nonmultimorbid, for each
definition.
Despite focusing on the community dwelling, working-
age population, the prevalence of MSK observed here
(36%) is fairly similar to (32% [3,48]; and 39% [14]) or
higher than (18% [20]; 23% [21]; and 25% [33]) studies
primarily focused on older and/or clinical populations. This
may be explained by our broader inclusion of MSK
compared with the selective inclusion within other studies,
as well as differences between countries of origin. The
range of multimorbidity prevalence in this study(20.2e75.4%) encompasses the multimorbidity prevalence
range observed within other MSK populations: 64% and
67% among those with rheumatoid arthritis and fibromyal-
gia, respectively [21], whereas among those with painful
conditions, 21% had one other condition, 21% had 2 other
conditions, and 47% had 3þ other conditions [7].
Our findings contrast with previous studies which sug-
gest competing demands of conditions may be associated
with lower likelihood of prescribing for MSK conditions
[16,49]. The counterintuitive increased likelihood of MSK
medicines use among those with multimorbidity may sug-
gest greater MSK disease progression or symptom severity
for those with multimorbidity. Alternatively, one of the
additional conditions might include another MSK (such
as coexisting osteoporosis and osteoarthritis), thereby
increasing likelihood of using MSK medicines.
Previous studies, two within UK primary care popula-
tions [39,43] of 3,145 patients aged 39e79 years [39] and
one in a random population-based survey of 2,192 adults
conducted in Spain [44], also identified additional subjec-
tive health burden associated with multimorbidity among
people with subsets of MSK (arthritis [39], rheumatic con-
ditions [44], and osteoarthritis [43]). Specifically, greater
association between multimorbidity and poor quality of life
(HRQoL) was observed: for multimorbidity that included
rheumatic conditions compared to those that did not [44],
and associations with poor HRQoL increased with
increasing number of conditions among those with arthritis
[arthritis plus one condition odds ratio (OR) 5 1.5 (95%
CI: 1.3e1.7), and plus two additional conditions
OR 5 3.0 (95% CI: 2.1e4.1)] [39]. However, effect sizes
were lower compared to here. This may be due to differ-
ences in the range of conditions contributing to multimor-
bidity [39]. The third study found among those with
osteoarthritis, associations with poor physical function
increased with increasing number of conditions [2e3 con-
ditions: OR 5 2.0 (95% CI: 1.0e4.2), 4e5 conditions
OR 5 2.8 (95% CI: 1.4e5.6), and 6þ conditions:
OR 5 3.7 (95% CI: 1.8e7.4)] [43].
Although not specifically focused on MSK populations,
studies limited to primary care and elderly populations have
also compared associations between multimorbidity and
health status or HRQoL [8,32,50], physical functioning
[51], and distress [9] sometimes using a range of definitions
within the same population. Within a UK study, associa-
tions with poor physical function increased with increasing
number of conditions [2e3 conditions (OR 5 1.5; 95% CI:
1.4e1.7), 4e5 conditions (OR 5 2.7; 95% CI: 2.4e3.1),
and 6þ conditions (OR 5 4.4; 95% CI: 3.9e5.1)] [51].
A study of Canadian primary care practices (n 5 238
adults) found that although simple counts of chronic condi-
tions were associated with HRQoL, scale-based measures
outperformed simple counts [8]. Conversely, multimorbid-
ity measured by simple condition counts was not related
to psychological distress (OR 5 1.12; 95% CI:
0.97e1.29), whereas multimorbidity measured by the
125D. Lowe et al. / Journal of Clinical Epidemiology 78 (2016) 116e126Cumulative Illness Rating Scale (CIRS) was (OR 5 1.67;
95% CI: 1.19e2.37) and the likelihood of psychological
distress increased with each CIRS multimorbidity quintile
[9].
Similar to other studies, we combine a broad range of
MSK despite the clinical heterogeneity of these conditions
[17,19]. This extends multimorbidity research which exam-
ines subgroups of arthritis conditions [39], osteoarthritis
[43], and rheumatic conditions [44]. However, there is a
lack of understanding of whether health burden associated
with multimorbidity varies for specific subcategories of
MSK (particularly soft-tissue disorders, back pain, gout,
and osteoporosis). To aid prioritization efforts, this focus
is required in future research to identify subgroups of
MSK for which the burden of multimorbidity is particularly
problematic and whether there is an operationalization of
multimorbidity counts that best captures this burden.5. Conclusion
Three in four working-age individuals with any MSK
reported living with at least two other co-occurring condi-
tions (survey definition), more than one in three reported
at least two somewhat burdensome health priority area con-
ditions (policy definition), whereas one in five reported at
least two very burdensome conditions (research definition).
Among working-age Australians with MSK, those with
multimorbidity had increased likelihood of subjective
health burden, consulting (non-MSK) specialists and taking
pain and MSK medicines compared to those who do not
have multimorbidity, irrespective of multimorbidity defini-
tion used. These analyses highlight the level of additional
subjective health and health care utilization burden associ-
ated with multimorbidity within the MSK population. How-
ever, the use of dichotomous cut points obscures the
gradient of burden severity produced by multimorbidity
definitions that exclude potentially less burdensome condi-
tions. It is yet to be established if the additional subjective
health burden associated with different ways of operation-
alizing multimorbidity is similar among other disease-
specific (e.g., diabetes) populations and whether associa-
tions differ within particular subgroups of MSK conditions.References
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